Vitrolife AB (VITR.ST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in SEK.

Revenue Annual

0 1.5B 3B 4.5B 2020: 1.2B 2021: 1.7B 2022: 3.2B 2023: 3.5B 2024: 3.6B 2020 2021 2022 2023 2024

Gross Profit Annual

0 800M 1.6B 2.4B 2020: 767.7M 2021: 1B 2022: 1.8B 2023: 2B 2024: 2.1B 2020 2021 2022 2023 2024

Operating Income Annual

-4.5B -3B -1.5B 0 1.5B 3B 4.5B 2020: 370M 2021: 435M 2022: 654M 2023: -3.6B 2024: 783M 2020 2021 2022 2023 2024

Net Income Annual

-4.5B -3B -1.5B 0 1.5B 3B 4.5B 2020: 287.9M 2021: 344M 2022: 394M 2023: -3.9B 2024: 514M 2020 2021 2022 2023 2024

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

0 350M 700M 1.1B 2020: 356.4M 2021: 384M 2022: 636M 2023: 757M 2024: 907M 2020 2021 2022 2023 2024

Free Cash Flow Annual

0 300M 600M 900M 2020: 349.7M 2021: 359M 2022: 585M 2023: 690M 2024: 815M 2020 2021 2022 2023 2024

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.